Silo Pharma, Inc. (SILO) |
2.5628 -0.017 (-0.67%)
|
01-27 15:36 |
Open: |
2.52 |
Pre. Close: |
2.58 |
High:
|
2.595 |
Low:
|
2.52 |
Volume:
|
15,494 |
Market Cap:
|
8(M) |
|
|
Technical analysis |
as of: 2023-01-27 4:47:57 PM |
Overall:
|
|
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
Target: |
Six months: 5.78 One year: 7.66 |
Support: |
Support1: 2.34 Support2: 1.95 |
Resistance: |
Resistance1: 4.95 Resistance2: 6.55 |
Pivot: |
2.71  |
Moving Average: |
MA(5): 2.57 MA(20): 2.79 
MA(100): 4.23 MA(250): 6.33  |
MACD: |
MACD(12,26): -0.2 Signal(9): -0.2  |
Stochastic oscillator: |
%K(14,3): 21.5 %D(3): 19.5  |
RSI: |
RSI(14): 38.9  |
52-week: |
High: 12.44 Low: 0.17 |
Average Vol(K): |
3-Month: 445 (K) 10-Days: 25 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SILO ] has closed above bottom band by 22.7%. Bollinger Bands are 82.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 58 bars. This is a sign that the market may be about to initiate a new trend. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
2.6 - 2.61 |
2.61 - 2.63 |
Low:
|
2.48 - 2.5 |
2.5 - 2.52 |
Close:
|
2.54 - 2.57 |
2.57 - 2.59 |
|
Company Description |
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. |
Headline News |
Sun, 29 Jan 2023 Farm Silos: Uses, Benefits, and Disadvantages - Krishi Jagran
Sun, 29 Jan 2023 The reveal of Quirindi’s Silo Art Project - nbnnews.com.au
Sun, 29 Jan 2023 Quirindi silos interactive light show is officially open - The Northern Daily Leader
Fri, 27 Jan 2023 Fix Broken Customer Journeys: 5 Solutions to CX Silo Issues - CMSWire
Thu, 26 Jan 2023 Silo’s Charley Hampton signs with McLennan for softball - KXII
Tue, 24 Jan 2023 USAF to begin Minuteman III silo conversion to house Sentinel ICBM by decade's end - Breaking Defense
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: PNK |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
-1 (M) |
Shares Float |
0 (M) |
% Held by Insiders
|
9.867e+007 (%) |
% Held by Institutions
|
1.82e+006 (%) |
Shares Short
|
0 (K) |
Shares Short P.Month
|
0 (K) |
Stock Financials |
EPS
|
66260 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
0.03 |
Profit Margin (%)
|
5 |
Operating Margin (%)
|
594.7 |
Return on Assets (ttm)
|
-3 |
Return on Equity (ttm)
|
526.8 |
Qtrly Rev. Growth
|
71.2 |
Gross Profit (p.s.)
|
0 |
Sales Per Share
|
0 |
EBITDA (p.s.)
|
0 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
0 (M) |
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
PE Ratio
|
0 |
PEG Ratio
|
0 |
Price to Book value
|
82.9 |
Price to Sales
|
0 |
Price to Cash Flow
|
0 |
Stock Dividends |
Dividend
|
9930 |
Forward Dividend
|
0 |
Dividend Yield
|
386381% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|